Drug intelligence / Profile preview

Dorminow SL

Development stage: Unknown
Lead developer: Laboratório Gross
Modality: Small Molecules
Administration: Sublingual

Overview

Dorminow SL is a sublingual dietary supplement developed by Laboratório Gross, a Brazilian pharmaceutical company. It is a combination product containing melatonin and vitamin B6 (pyridoxine) formulated as oral drops. Melatonin acts as a chronobiotic by targeting melatonin receptors to regulate the circadian rhythm and reduce the time required to fall asleep. Vitamin B6 is included as a nutritional supplement to support energy metabolism and the proper functioning of the nervous system. The sublingual administration route is designed for rapid absorption and convenience, allowing the product to be taken immediately before sleep without the need for water.

Brand names: Dorminow SLDorminow

Targets

MTNR1A (MT1)

Beyond the preview

Go deeper on Dorminow SL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dorminow SL.

Explore the full profile